The ENCHANTED-MT trial is an investigator initiated and conducted, multicentre, prospective, randomised, open, blinded end-point assessed (PROBE) clinical trial. ENCHANTED-MT has the principle aim of determining the effectiveness of more blood pressure (BP) lowering management (systolic BP target <120 mmHg) compared to less intensive BP management range (systolic BP target 140-180 mmHg) in acute ischemic stroke (AIS) patients with large vessel occlusion (LVO), to improve functional outcomes after achieving successful recanalization from contemporary mechanical thrombectomy (MT) therapy. There are two embedded sub-studies evaluating different approaches to secondary prevention in this patient group: early versus delayed initiation of anticoagulation in those with associated atrial fibrillation (AF); and short versus conventional duration of dual antiplatelet therapy (DAPT) in those patients with a clear indication for such therapy following MT.

ENCHANTED-MT is one of the randomized clinical trials that will be conducted by National Health and Family Planning Commission of the People's Republic of China (ClinicalTrials.gov Identifier: NCT04140110) .

The upper menu helps you to navigate through this website and access more information about this trial.

Kind regards

On behalf of the ENCHANTED-MT executive committee

ENCHANTED-MT principle investigators